Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

Abstract: A copolymer is excellent in water permeability, suppression of platelet adhesion, and suppression of protein adhesion, and a separation membrane, a medical device, and a separation membrane module for medical use using the copolymer. The copolymer includes monomer units derived from two or more types of monomers, wherein the hydration energy density of the copolymer is 158.992 to 209.200 kJ·mol?1·nm?3, the monomer unit with the highest hydration energy density in the monomer units is a monomer unit not containing a hydroxy group, the volume fraction of the monomer unit with the highest hydration energy density in the monomer units is 35 to 90%, and the difference in hydration energy density is 71.128 to 418.400 kJ·mol?1·nm?3.

Abstract: A motion picture distribution system is provided with: an extractor configured to perform an extraction operation of extracting one or a plurality of scenes associated with a particular action of a target person from a motion picture taken by an imager; a generator configured to edit the extracted one or plurality of scenes and to generate a digest motion picture; and a distributor configured to distribute the generated digest motion picture. The extractor is configured to perform machine learning associated with the particular action, by using at least a part of a motion picture including a person as input data, in order to improve the extraction operation.

Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn wider an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.

Abstract: In an aspect, the present invention provides a structure, a structure-manufacturing method, a cell-sorting method, or the like. In an aspect, a structure (1) of the present invention is a structure including a first substrate (10) and a second substrate (20) disposed to face one side of the first substrate (10), in which the first substrate (10) has a plurality of depressions (11) which are open to the other side of the first substrate and each of which has a size that enables each of the depressions to capture one unit of a cell, at least some of the depressions (11) have communication holes (12) which communicate with one side and the other side of the first substrate and each of which has a size that enables secretions secreted from the cell to move through the communication holes, the second substrate (20) can include accumulation portions (13) in which the secretions moving through the communication holes (12) are accumulated, and the accumulation portions (13) can correspond to the depressions (11).

Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.

Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

Abstract: An optical modulation device includes: an optical waveguide formed above a substrate; a phase modulator disposed on part of the optical waveguide; a capacitor connected to the phase modulator and including a lower electrode and an upper electrode; a resistor connected in parallel to the capacitor; and an appended part integrated with the upper electrode and electrically connected to the resistor, wherein the appended part is smaller in area than the capacitor (upper electrode).

Abstract: A stent includes a wavy-shaped member extending circumferentially, and expandable and contractable in the radial direction of the stent. The wavy-shaped member includes a pair of straight parts, an apex part and an opening. The ends of the apex part are connected to the straight parts. The opening is positioned at least in the apex part. The apex part has a link part at the outer circumference side of the opening, and a base part at the inner circumference side of the opening. The base part has a curved inner circumference and the link part lies across a vertex of the base part. The width of the link part in relation to the circumferential direction of the stent is smaller than the width of the base part in relation to the circumferential direction of the stent, at the vertex of the base part.

Abstract: An optical modulation device includes: an optical waveguide formed above a substrate; a phase modulator disposed on part of the optical waveguide; a capacitor connected to the phase modulator and including a lower electrode and an upper electrode; a resistor connected in parallel to the capacitor; and an appended part integrated with the upper electrode and electrically connected to the resistor, wherein the appended part is smaller in area than the capacitor (upper electrode).

Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.

Abstract: A stent and method of exhibiting radiopaque properties in a stent are disclosed, which includes a stent main body that is made of a metal, and a radiopaque marker that is made of a complete solid solution alloy having a corrosion potential of ±200 mV of a corrosion potential of the metal of the stent main body.

Abstract: A relay busbar device of one embodiment is a relay busbar device with a built-in current sensor, which is interposed between a motor casing and an inverter casing, and includes a relay busbar both ends of which enter into both of the casings; a resin plate, through which the relay busbar penetrates, and which is interposed between the two casings; a magnetic core, positioned within the resin plate and surrounding the relay busbar; and a magnetic sensor provided in a removed portion of the magnetic core. The relay busbar is mold-formed integrally with the resin plate during resin molding thereof, and changes in magnetic field occurring in the removed portion due to the current flowing in the relay busbar are detected by the magnetic sensor, and the value of the current flowing in the relay busbar is measured.

Abstract: A stent which can suppress galvanic corrosion while radiopacity is sufficiently ensured. The stent includes a sintered body of a base material that is formed of a first metal material with a second metal material that is dispersed in the base material. The second metal material has a specific gravity higher than that of the first metal material, and has a corrosion potential expressed by a corrosion potential of the first metal material ±200 mV.

Abstract: The present optical modulator includes an optical waveguide core made of a semiconductor material, an electrode, and a plurality of channels made of a semiconductor material doped in an n type or a p type and electrically connecting the optical waveguide core and the electrode to each other. The plurality of channels are provided in a spaced relationship from each other along a propagation direction of light; the optical waveguide core includes a doped region doped in the n type or the p type and a non-doped region. The doped region and the non-doped region are disposed alternately along the propagation direction of light. Each of the plurality of channels is connected to the doped region.

Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.